2024 Middlefield Rd, Redwood City, CA 94063 4158677734
Alice Y. Ho Medical Doctor
Jennifer L Hay PH.D Health/Allied Services
1275 York Ave, New York, NY 10065
Alice Yoosun Ho
Alice Ho MD Radiology
1275 York Ave, New York, NY 10065 2126392000
Alice L Ho Owner
HIGH PEARL RESTAURANT INC Eating Place
82-20 45 Ave, Elmhurst, NY 11373 8222 45 Ave, Flushing, NY 11373 7184783330
Alice Ho Pathologist
Memorial Sloan-Kettering Cancer Center Inc Social Services Specialty Hospital · Allergist · Anesthesiology · Hematologists · Oncology · Pediatric Oncologist · Thoracic Surgery · Dentists
1275 York Ave, New York, NY 10065 633 3 Ave, New York, NY 10017 6462273490, 2126392000, 6462273535, 2126393576
Jun 2009 to 2000 Medical AssistantLong Island University Brooklyn, NY Jan 2014 to May 2014 Teacher AssistantLong Island University Brooklyn, NY Sep 2012 to Dec 2013 Graduate AssistantLong Island University Brooklyn, NY Jan 2013 to May 2013 Parkinson's Fitness Program InternLutheran Medical Center Brooklyn, NY Jul 2008 to May 2012 Volunteer
Education:
Long Island University Brooklyn, NY 2014 Masters of Science in Exercise Science
Skills:
Computer <br/> Microsoft Word, PowerPoint, and Excel<br/>Language<br/> Fluent in conversational Cantonese and Mandarin
Dennis G. Ballinger - Menlo CA John Ford - San Mateo CA Alice Suk-Yue Ho - Union City CA Hai Shan Lin - Castro Valley CA Ann M. Pace - Scotts Valley CA
The present invention provides novel nucleic acids encoding IL-1 Hy2, a novel member of the Interleukin-1 Receptor Antagonist family, the novel polypeptides encoded by these nucleic acids and uses of these and related products.
Kevin W. Moore - Palo Alto CA Ying Liu - Mountain View CA Alice Suk-Yue Ho - Milpitas CA Bazan Fernando J. - Menlo Park CA Jimmy C. Tan - Edison NJ Chuan-Chu Chou - Westfield NJ
Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.
John Ford - San Mateo CA Alice Suk-Yue Ho - Union City CA
Assignee:
Hyseq, Inc. - Sunnyvale CA
International Classification:
A61K 4500
US Classification:
424 852, 514 2, 530351
Abstract:
The present invention provides novel therapeutic methods of administering an amount of IL-1Ra to treat IL-18 related disorders. Specifically, the method involves treating IL-18 related disorders such as liver injury, hepatis, hemophagocytic lymphohistiocytosis, multiple sclerosis, tumors, cytotoxicity resulting from antitumor therapy, or other autoimmune disorders with a therapeutically effective amount of IL-1ra, and optionally measuring IFN- and IL-18 activity from human samples.
Interleukinâ1 Receptor Antagonist And Uses Thereof
John Ford - San Mateo CA Alice Suk-Yue Ho - Union City CA Ann Pace - Scotts Valley CA
Assignee:
Hyseq, Inc. - Sunnyvale CA
International Classification:
C07H 2104
US Classification:
536 243, 4352872, 4352883, 4352884, 536 231
Abstract:
The present invention provides novel nucleic acids, the novel polypeptide sequences encoded by these nucleic acids and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist.
Dennis Ballinger - Menlo Park CA, US John Ford - San Diego CA, US Alice Ho - Palo Alto CA, US Haishan Lin - Castro Valley CA, US Ann Pace - Scotts Valley CA, US Nancy Mize - Mountain View CA, US
International Classification:
A61K038/17 C07K014/435
US Classification:
514/012000, 530/350000
Abstract:
The present invention provides machine readable storage media comprising a three-dimensional representation of Interleukin-1 Hy2 (IL-1Hy2), useful for designing and producing modulators of its activity and IL-1 Hy2 variants, and therapeutic uses thereof. The present invention also provides novel nucleic acids encoding IL-1 Hy2, the novel polypeptides encoded by these nucleic acids and uses of these and related products.
Treatment Of Immune Disorders And B Cell Disorders
Alice Ho - Palo Alto CA, US John Ford - San Diego CA, US Hai-Shan Lin - Castro Valley CA, US Fabio Rupp - Sunnyvale CA, US
International Classification:
A61K039/395
US Classification:
424/145100
Abstract:
The present invention provides materials and methods of using compositions comprising the IL-1Hy1 polypeptide or inhibitors of IL-1Hy1 activity for treatment of immune cell disorders.
Methods And Materials Relating To Prothrombinase-Like Polypeptides And Polynucleotides
Bryan Boyle - San Francisco CA, US Alice Ho - Palo alto CA, US PING Zhou - Cupertino CA, US Nancy Mize - Mountain View CA, US Chiaoyun Kuo - San Jose CA, US Matthew Arterburn - San Jose CA, US Y. Tom Tang - San Jose CA, US Chenghua Liu - San Jose CA, US Radoje Drmanac - Palo Alto CA, US
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel secreted prothrombinase-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human ovary (Hyseq clone identification numbers 773565 (SEQ ID NO: 1) and 7727065 (SEQ ID NO: 11)). Other aspects of the invention include vectors containing processes for producing novel secreted prothrombinase-like polypeptides, and antibodies specific for such polypeptides.
Kevin W. Moore - Palo Alto CA Ying Liu - Mountain View CA Alice Suk-Yue Ho - Milpitas CA J. Fernando Bazan - Menlo Park CA Jimmy C. Tan - Edison NJ Chuan-Chu Chou - Westfield NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12N 1512
US Classification:
435 691
Abstract:
Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.